Indication
Streptococcus pneumoniae chronic bronchitis
This indication refers to an acute bacterial infection of the lower respiratory tract, typically presenting as an acute bacterial exacerbation of chronic bronchitis (frequently evaluated in the context of chronic obstructive pulmonary disease) caused by the Gram-positive pathogen *Streptococcus pneumoniae*. Read more about Streptococcus pneumoniae chronic bronchitis
145 drugs 76 manufacturers
Drugs that treat it
Common Streptococcus pneumoniae chronic bronchitis therapies.
SULFAMETHOXAZOLE-TRIMETHOPRIM (sulfamethoxazole/trimethoprim)
MOXIFLOXACIN HCL
MOXIFLOXACIN (moxifloxacin HCl in sodium chloride, iso-osmotic)
SULFAMETHOXAZOLE-TRIMETHOPRIM (sulfamethoxazole/trimethoprim)
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThis indication refers to an acute bacterial infection of the lower respiratory tract, typically presenting as an acute bacterial exacerbation of chronic bronchitis (frequently evaluated in the context of chronic obstructive pulmonary disease) caused by the Gram-positive pathogen *Streptococcus pneumoniae*.
The condition primarily affects adults with preexisting chronic bronchial inflammation and airflow limitation, such as long-term smokers or those with underlying lung disease.
Pathophysiologically, pneumococcal invasion of the chronically inflamed airways leads to epithelial injury, heightened neutrophilic inflammation, and compromised mucociliary clearance.
This process clinically manifests as a sudden, sustained deterioration beyond baseline symptoms, specifically characterized by increased dyspnea, increased sputum volume, and heightened sputum purulence.
- fda.gov
This indication refers to an acute bacterial infection of the lower respiratory tract, typically presenting as an acute bacterial exacerbation of chronic bronchitis (frequently evaluated in the context of chronic obstructive pulmonary disease) caused by the Gram-positive pathogen *Streptococcus pneumoniae* The condition primarily affects adults with preexisting chronic bronchial inflammation and airflow limitation, such as long-term smokers or those with underlying lung disease
- ajmc.com
The condition primarily affects adults with preexisting chronic bronchial inflammation and airflow limitation, such as long-term smokers or those with underlying lung disease This process clinically manifests as a sudden, sustained deterioration beyond baseline symptoms, specifically characterized by increased dyspnea, increased sputum volume, and heightened sputum purulence
- ersnet.org
Pathophysiologically, pneumococcal invasion of the chronically inflamed airways leads to epithelial injury, heightened neutrophilic inflammation, and compromised mucociliary clearance This process clinically manifests as a sudden, sustained deterioration beyond baseline symptoms, specifically characterized by increased dyspnea, increased sputum volume, and heightened sputum purulence
Personalize your experience
Follow Streptococcus pneumoniae chronic bronchitis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.